Monitor the final IPO pricing and whether the offering closes, as the company's existing cash is only expected to fund operations into Q1 fiscal 2027. Watch for progress on the NRC license application submission (targeted Q1 2027) and any additional DOE task orders under the IDIQ contract, as these are key milestones for the pre-revenue business.
How similar events traded
Executive Summary
LIS Technologies filed Amendment No. 2 to its S-1 for an IPO of 3,100,000 shares (up from 2,833,334 in the prior amendment) at an assumed price of $5.00-$7.00 per share, with net proceeds estimated at $16.4 million. The company is an early-stage uranium enrichment developer using the patented CRISLA laser process, has generated no revenue to date, and has an accumulated deficit of $65.4 million as of July 31, 2026. Proceeds will fund R&D, business development, and working capital.
Key Financial Metrics
Key Facts
- IPO of 3,100,000 shares (3,565,000 with full over-allotment) at assumed price of $5.00-$7.00 per share, midpoint $6.00
- Net proceeds estimated at approximately $16.4 million, or $19.0 million if over-allotment exercised in full
- No revenue generated since inception; accumulated deficit of $65,418,743 as of July 31, 2026
- Net loss of $29,688,039 for the nine months ended July 31, 2026; cash of $18,791,693 as of July 31, 2026
- Cash used in operating activities of $14,819,401 and cash used in investing activities of $24,875,909 for the nine months ended July 31, 2026
- Existing cash expected to fund operations only into the first quarter of fiscal 2027; management estimates $74 million cash requirements for the twelve months ending July 31, 2027
- CRISLA process assessed at TRL 4; plans to submit NRC license application in Q1 2027 with review estimated at 18 months
- Planned LEU-3 Facility capital investment estimated at approximately $1.38 billion, with operations targeted around 2033
- Selected as one of six participants in DOE LEU acquisition program under a ten-year IDIQ contract
- CEO Jay Jiang Yu and President Christo Liebenberg each indicated interest in purchasing up to $250,000 of shares in the offering
- Underwriters granted 30-day option for 465,000 additional shares and Representative's Warrant for 217,000 shares at 115% of IPO price
- Immediate dilution of $5.32 per share to new investors at assumed $6.00 IPO price
Financial Impact
IPO expected to raise approximately $16.4 million in net proceeds at assumed $6.00 per share price; company has no revenue and accumulated deficit of $65.4 million
Risk Factors
- No revenue generated to date and no expectation of meaningful revenue for several years
- Going concern risk: existing cash expected to fund operations only into Q1 fiscal 2027, requiring substantial additional capital
- Unproven technology at TRL 4; CRISLA process has not been demonstrated at commercial scale
- Dependence on obtaining NRC license and other regulatory approvals for commercial enrichment facility
- Planned LEU-3 Facility requires approximately $1.38 billion in capital, far exceeding IPO proceeds
- Heavy reliance on related party NANO Nuclear for strategic, technical, and commercial support
- Voluntary self-disclosure to NNSA in September 2026 regarding violations of 10 CFR Part 810 export control provisions
- Document contains text addressed to automated readers
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-052907 |
| Exhibit: ex1-1.htm | 0001493152-26-052907 |
Track record
2 reports on LIS
Filters
- Nov 17, 20264d ago S-1/A Neutral 5/10 Viewing No price data
- Nov 5, 202616d ago S-1/A Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers